Adamas files for IPO

CNS company Adamas Pharmaceuticals Inc. (Emeryville, Calif.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by Credit Suisse; Piper Jaffray; William Blair; and Needham. This year, Adamas plans to start a Phase III trial of ADS-5102 to treat levodopa-induced dyskinesia. An NDA submission for the oral extended-release formulation of amantadine is slated for 1H16. Last year, Adamas said once-daily doses of ADS-5102 improved dyskinesia in patients with Parkinson's disease (PD) in the Phase II/III EASED trial (see BioCentury Extra, June 18, 2013). ...